121 related articles for article (PubMed ID: 31533005)
1. LNX1 contributes to tumor growth by down-regulating p53 stability.
Park R; Kim H; Jang M; Jo D; Park YI; Namkoong S; Lee JI; Jang IS; Park J
FASEB J; 2019 Dec; 33(12):13216-13227. PubMed ID: 31533005
[TBL] [Abstract][Full Text] [Related]
2. Regulation of Mdm2 protein stability and the p53 response by NEDD4-1 E3 ligase.
Xu C; Fan CD; Wang X
Oncogene; 2015 Jan; 34(3):281-9. PubMed ID: 24413081
[TBL] [Abstract][Full Text] [Related]
3. Cooperation of Musashi-2, Numb, MDM2, and P53 in drug resistance and malignant biology of pancreatic cancer.
Sheng W; Dong M; Chen C; Wang Z; Li Y; Wang K; Li Y; Zhou J
FASEB J; 2017 Jun; 31(6):2429-2438. PubMed ID: 28223335
[TBL] [Abstract][Full Text] [Related]
4. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
5. TRIAD1 inhibits MDM2-mediated p53 ubiquitination and degradation.
Bae S; Jung JH; Kim K; An IS; Kim SY; Lee JH; Park IC; Jin YW; Lee SJ; An S
FEBS Lett; 2012 Sep; 586(19):3057-63. PubMed ID: 22819825
[TBL] [Abstract][Full Text] [Related]
6. A network of substrates of the E3 ubiquitin ligases MDM2 and HUWE1 control apoptosis independently of p53.
Kurokawa M; Kim J; Geradts J; Matsuura K; Liu L; Ran X; Xia W; Ribar TJ; Henao R; Dewhirst MW; Kim WJ; Lucas JE; Wang S; Spector NL; Kornbluth S
Sci Signal; 2013 May; 6(274):ra32. PubMed ID: 23652204
[TBL] [Abstract][Full Text] [Related]
7. TRIAD1 is negatively regulated by the MDM2 E3 ligase.
Bae S; Jung JH; An IS; Kim OY; Lee MJ; Lee JH; Park IC; Lee SJ; An S
Oncol Rep; 2012 Nov; 28(5):1924-8. PubMed ID: 22940738
[TBL] [Abstract][Full Text] [Related]
8. TRIM25 has a dual function in the p53/Mdm2 circuit.
Zhang P; Elabd S; Hammer S; Solozobova V; Yan H; Bartel F; Inoue S; Henrich T; Wittbrodt J; Loosli F; Davidson G; Blattner C
Oncogene; 2015 Nov; 34(46):5729-38. PubMed ID: 25728675
[TBL] [Abstract][Full Text] [Related]
9. RFWD3-Mdm2 ubiquitin ligase complex positively regulates p53 stability in response to DNA damage.
Fu X; Yucer N; Liu S; Li M; Yi P; Mu JJ; Yang T; Chu J; Jung SY; O'Malley BW; Gu W; Qin J; Wang Y
Proc Natl Acad Sci U S A; 2010 Mar; 107(10):4579-84. PubMed ID: 20173098
[TBL] [Abstract][Full Text] [Related]
10. microRNA-1827 represses MDM2 to positively regulate tumor suppressor p53 and suppress tumorigenesis.
Zhang C; Liu J; Tan C; Yue X; Zhao Y; Peng J; Wang X; Laddha SV; Chan CS; Zheng S; Hu W; Feng Z
Oncotarget; 2016 Feb; 7(8):8783-96. PubMed ID: 26840028
[TBL] [Abstract][Full Text] [Related]
11. miR-100 antagonism triggers apoptosis by inhibiting ubiquitination-mediated p53 degradation.
Yang G; Gong Y; Wang Q; Wang L; Zhang X
Oncogene; 2017 Feb; 36(8):1023-1037. PubMed ID: 27524417
[TBL] [Abstract][Full Text] [Related]
12. 2-Methoxy-5((3,4,5-trimethosyphenyl)seleninyl) phenol inhibits MDM2 and induces apoptosis in breast cancer cells through a p53-independent pathway.
Xu J; Han M; Shen J; Guan Q; Bai Z; Lang B; Zhang H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2016 Dec; 383(1):9-17. PubMed ID: 27693458
[TBL] [Abstract][Full Text] [Related]
13. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
14. Mouse models of Mdm2 and Mdm4 and their clinical implications.
Xiong S
Chin J Cancer; 2013 Jul; 32(7):371-5. PubMed ID: 23327795
[TBL] [Abstract][Full Text] [Related]
15. Primate-specific miR-944 activates p53-dependent tumor suppression in human colorectal cancers.
Kim YJ; Lee JH; Jin S; Kim JH; Kim SH
Cancer Lett; 2019 Jan; 440-441():168-179. PubMed ID: 30393117
[TBL] [Abstract][Full Text] [Related]
16. MDM2 Associates with Polycomb Repressor Complex 2 and Enhances Stemness-Promoting Chromatin Modifications Independent of p53.
Wienken M; Dickmanns A; Nemajerova A; Kramer D; Najafova Z; Weiss M; Karpiuk O; Kassem M; Zhang Y; Lozano G; Johnsen SA; Moll UM; Zhang X; Dobbelstein M
Mol Cell; 2016 Jan; 61(1):68-83. PubMed ID: 26748827
[TBL] [Abstract][Full Text] [Related]
17. Aciculatin induces p53-dependent apoptosis via MDM2 depletion in human cancer cells in vitro and in vivo.
Lai CY; Tsai AC; Chen MC; Chang LH; Sun HL; Chang YL; Chen CC; Teng CM; Pan SL
PLoS One; 2012; 7(8):e42192. PubMed ID: 22912688
[TBL] [Abstract][Full Text] [Related]
18. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
19. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
